IncellDx HPV OncoTect 3Dx system combines the quantification of oncogene mRNA overexpression, proliferation, and aneuploidy in one high-throughput assay, according to the firm.
The company said it also saw record cash collections in the quarter despite challenges caused by regulatory change.
The assay correlates shortened telomere lengths in patients of different ages to potential risks for inherited diseases, such as bone marrow failure syndrome and liver cancer.
The firm plans to expedite cell sorting for research labs with an inexpensive device that uses piezoelectric actuators and disposable microfluidics.
Separately, FlowJo and Cytapex Bioinformatics said they have partnered to provide bioinformatics consulting and services for flow cytometry data analysis.
The researchers reported that their assay could detect women with defective double-stranded break repair pathways even when sequencing could not.
With tens of thousands of immune cell measurements for almost 500 individuals, researchers saw enhanced genetic influence over some adaptive immune traits.
The certification enables the company to offer its flow cytometry-based myeloid-derived suppressor cell assay for cancer patients.
At the American Association for Clinical Chemistry meeting, Theranos CEO Elizabeth Holmes said her company is working on third-party review and publications of the firm's technologies and tests.
Researchers working on the Human Functional Genomics Project have begun to unravel genetic relationships and variations in human immune response.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.
NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.
CNBC reports that there are thousands of genetic tests available for consumers to chose between.
In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.